Tenax Therapeutics enters supply agreement with Orion; extends regulatory approval deadline to 2035

TENAX THERAPEUTICS, INC.

Supply Agreement with Orion for oral levosimendan; 5-year initial term, auto-renewing 3-year periods.
Sixth Amendment extends U.S. regulatory approval deadline to December 31, 2035; failure allows termination.
Company must comply with Orion's General Information and Cybersecurity Requirements as part of amendment.
Supply Agreement includes cost-sharing provisions for scaling Orion's manufacturing capabilities.
Either party may terminate for material breach (60-day cure) or insolvency; also tied to License Agreement termination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.